ArticlePloS one2025
Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Influenza Vaccines for Persons Who Are Immunocompromised: A Scoping Review of the Literature.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza is especially dangerous for high-risk patients, for whom various vaccination strategies are used to prevent this disease. This study assessed the safety and immunological effectiveness of an inactivated trivalent polymer-subunit influenza vaccine Grippol® Plus administered according to two regimens in a group of 41 patients with severe progressive bronchopulmonary disorders. It also investigated the duration of vaccine-induced antibody response in this patient population. Group 1 of the study subjects (n = 21) received one dose of Grippol® Plus, and Group 2 (n = 20) received two doses of Grippol® Plus one month apart in the same influenza season. To measure antibody levels, paired sera were tested in hemagglutination inhibition assay pre-vaccination and at months 1 and 12 post-vaccination. Vaccine immunogenicity was assessed by the Committee for Medicinal Products for Human Use (CHMP) criteria. All patients were symptom-free in the post-vaccination period. The one-dose regimen met all CHMP criteria against strains A/California/7/2009(H1N1)pdm09-like and A/Texas/50/2012(H3N2) and the criteria for seroprotection and seroconversion against the B/Massachusetts/2/2012 strain. This regimen was associated with a significant increase in Ab titers against all the three influenza viral strains. In the two-dose group, no statistically significant differences were observed in IgG Ab levels, seroprotection rate, seroconversion rate or seroconversion factor at month 1 after the first and second vaccine doses. At month 12 post-vaccination, Ab levels returned to baseline, regardless the vaccination regimen. In lung transplant candidates, one-dose vaccination with an inactivated trivalent polymer-subunit influenza vaccine was effective in generating protective antibody levels for the current influenza season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.